Neoss Launches NeoGenix XP™

Safe and Clinically Proven Natural Bone Substitute

Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XP™ this autumn to our existing product portfolio.

NeoGenix XP™ is a safe and clinically proven natural bone substitute, that closer resembles natural bone than those of synthetic materials, such as hydroxyapatite or tricalcium phosphate.

Surface roughness affects cellular response, enhancing cell adhesion and proliferation and possibly other markers of expression of cell phenotype, like production of collagen type I, osteocalcin, extracellular matrix, and mineralized material.

“Being a strong partner to our customers has always been important and offering more in terms of total package solutions. NeoGenix XP™ is an important addition to this and strengthens not only the bone regeneration portfolio but will allow us to serve our customer even better!” —Dr Robert Gottlander, Neoss CEO

This exciting product line will add new dimensions to Neoss existing Bone Regeneration offering, providing an enhanced offering of Bone materials and membranes.

Neoss maintains its clear focus on innovation and has a continuous plan of new market leading product solutions that will be presented over the next few years. All with the same target of introducing smart products that are intuitively easy to use with Intelligent Simplicity.

More here.

 

SourceNeoss®
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy